Skip to search formSkip to main contentSkip to account menu

SCH 42495

Known as: SCH-42495 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Methionine
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2002
2002
Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes
Objective The effects of combined inhibition of neutral endopeptidase (NEP) with either angiotensin-converting enzyme (ACE), or… 
1999
1999
Brain natriuretic peptide and neutral endopeptidase inhibition in left ventricular impairment.
Brain natriuretic peptide (BNP) is increased in left ventricular impairment and neutral endopeptidase (NEP) is involved in its… 
Highly Cited
1998
Highly Cited
1998
Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus.
It has been suggested that combined inhibition of angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP) may lower… 
1997
1997
Inhibition of neutral endopeptidase, the degradative enzyme for natriuretic peptides, in rat kidney after oral SCH 42495.
1. Inhibition of neutral endopeptidase (NEP), the degradative enzyme for atrial natriuretic peptide, was studied in vitro and in… 
Review
1996
Review
1996
Neutral endopeptidase inhibitors and the pulmonary circulation.
1994
1994
Antihypertensive effects of the neutral endopeptidase inhibitor SCH 42495 in essential hypertension.
The antihypertensive effects and safety of a novel neutral endopeptidase inhibitor, SCH 42495, were investigated in hypertensive… 
1994
1994
Effects of the neutral endopeptidase inhibitor, SCH 42495, on the cardiovascular remodelling secondary to chronic hypoxia in rats.
1. We have investigated the effects of inhibition of neutral endopeptidase on the cardiovascular remodelling secondary to chronic… 
Highly Cited
1993
Highly Cited
1993
Endopeptidase 24.11 inhibition by SCH 42495 in essential hypertension.
The detailed integrated renal, hormonal, and hemodynamic effects of acute (first dose) and established (4 days) inhibition of… 
1993
1993
Atrial natriuretic factor potentiating and hemodynamic effects of SCH 42495, a new, neutral metalloendopeptidase inhibitor.
Neutral metalloendopeptidase (NEP) inhibitors delay atrial natriuretic factor (ANF) catabolism and potentiate biological… 
1993
1993
Plasma brain natriuretic peptide and endopeptidase 24.11 inhibition in hypertension.
In contrast to the wealth of information available concerning the response of plasma atrial natriuretic peptide to changes in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)